Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 73,052 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004775 · doc4.xml · derivative · entry 6 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,052 Underlying: Common Stock · 73,052 shares Expires 2022-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
Lewis-Hall Freda CExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 103,155 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-17-004775 · doc4.xml · derivative · entry 5 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103,155 shares Expires 2017-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
Lewis-Hall Freda CExecutive Vice President
|
Tax withholdingCommon Stock | 49,942 | $32.49 | $1,622,615.58 |
DisclosureSEC source: 0001225208-17-004775 · doc4.xml · nonDerivative · entry 3 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,230 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
Lewis-Hall Freda CExecutive Vice President
|
Tax withholdingCommon Stock | 23,184 | $34.06 | $789,647.04 |
DisclosureSEC source: 0001225208-17-004775 · doc4.xml · nonDerivative · entry 2 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,172 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
Lewis-Hall Freda CExecutive Vice President
|
Exercise / conversionCommon Stock | 103,155 | $21.03 | $2,169,349.65 |
DisclosureSEC source: 0001225208-17-004775 · doc4.xml · nonDerivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
LUND-JURGENSEN KIRSTENExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 26,954 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004777 · doc4.xml · derivative · entry 6 LUND-JURGENSEN KIRSTEN · CIK 0001693493 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,954 Underlying: Common Stock · 26,954 shares Expires 2024-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
LUND-JURGENSEN KIRSTENExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 32,468 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004777 · doc4.xml · derivative · entry 5 LUND-JURGENSEN KIRSTEN · CIK 0001693493 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,468 Underlying: Common Stock · 32,468 shares Expires 2022-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
LUND-JURGENSEN KIRSTENExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 21,238 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-17-004777 · doc4.xml · derivative · entry 4 LUND-JURGENSEN KIRSTEN · CIK 0001693493 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,238 shares Expires 2017-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
LUND-JURGENSEN KIRSTENExecutive Vice President
|
Tax withholdingCommon Stock | 10,282 | $32.49 | $334,062.18 |
DisclosureSEC source: 0001225208-17-004777 · doc4.xml · nonDerivative · entry 3 LUND-JURGENSEN KIRSTEN · CIK 0001693493 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,729 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
LUND-JURGENSEN KIRSTENExecutive Vice President
|
Tax withholdingCommon Stock | 3,837 | $34.06 | $130,688.22 |
DisclosureSEC source: 0001225208-17-004777 · doc4.xml · nonDerivative · entry 2 LUND-JURGENSEN KIRSTEN · CIK 0001693493 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,011 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
LUND-JURGENSEN KIRSTENExecutive Vice President
|
Exercise / conversionCommon Stock | 21,238 | $21.03 | $446,635.14 |
DisclosureSEC source: 0001225208-17-004777 · doc4.xml · nonDerivative · entry 1 LUND-JURGENSEN KIRSTEN · CIK 0001693493 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 90,970 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004776 · doc4.xml · derivative · entry 7 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,970 Underlying: Common Stock · 90,970 shares Expires 2024-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 109,578 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004776 · doc4.xml · derivative · entry 6 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,578 Underlying: Common Stock · 109,578 shares Expires 2022-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 51,578 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-17-004776 · doc4.xml · derivative · entry 5 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,578 shares Expires 2017-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 24,971 | $32.49 | $811,307.79 |
DisclosureSEC source: 0001225208-17-004776 · doc4.xml · nonDerivative · entry 3 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,966 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 9,821 | $34.06 | $334,503.26 |
DisclosureSEC source: 0001225208-17-004776 · doc4.xml · nonDerivative · entry 2 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,937 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Exercise / conversionCommon Stock | 51,578 | $21.03 | $1,084,685.34 |
DisclosureSEC source: 0001225208-17-004776 · doc4.xml · nonDerivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:47 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 45,485 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004780 · doc4.xml · derivative · entry 5 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,485 Underlying: Common Stock · 45,485 shares Expires 2024-02-23 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:47 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 54,789 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004780 · doc4.xml · derivative · entry 4 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,789 Underlying: Common Stock · 54,789 shares Expires 2022-02-23 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:47 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
Tax withholdingCommon Stock | 12,983 | $34.06 | $442,200.98 |
DisclosureSEC source: 0001225208-17-004780 · doc4.xml · nonDerivative · entry 2 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,049 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:47 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
GrantCommon Stock | 30,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004780 · doc4.xml · nonDerivative · entry 1 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,032 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:47 UTC |
OLSON LAURIE JExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 27,965 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004781 · doc4.xml · derivative · entry 7 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,965 Underlying: Common Stock · 27,965 shares Expires 2024-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:47 UTC |
OLSON LAURIE JExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 33,685 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004781 · doc4.xml · derivative · entry 6 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,685 Underlying: Common Stock · 33,685 shares Expires 2022-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:47 UTC |
OLSON LAURIE JExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 27,306 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-17-004781 · doc4.xml · derivative · entry 5 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,306 shares Expires 2017-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:47 UTC |
OLSON LAURIE JExecutive Vice President
|
Tax withholdingCommon Stock | 13,220 | $32.49 | $429,517.80 |
DisclosureSEC source: 0001225208-17-004781 · doc4.xml · nonDerivative · entry 3 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,741 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:47 UTC |
OLSON LAURIE JExecutive Vice President
|
Tax withholdingCommon Stock | 5,263 | $34.06 | $179,257.78 |
DisclosureSEC source: 0001225208-17-004781 · doc4.xml · nonDerivative · entry 2 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,961 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:47 UTC |
OLSON LAURIE JExecutive Vice President
|
Exercise / conversionCommon Stock | 27,306 | $21.03 | $574,245.18 |
DisclosureSEC source: 0001225208-17-004781 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:55 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantStock Appreciation Rights · Derivative | 438,005 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004783 · doc4.xml · derivative · entry 8 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,005 Underlying: Common Stock · 438,005 shares Expires 2024-02-23 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:55 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantStock Appreciation Rights · Derivative | 527,597 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004783 · doc4.xml · derivative · entry 7 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 527,597 Underlying: Common Stock · 527,597 shares Expires 2022-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:55 UTC |
READ IAN CDirector · Chairman & CEO
|
Exercise / conversionStock Appreciation Rights · Derivative | 788,835 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-17-004783 · doc4.xml · derivative · entry 6 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 788,835 shares Expires 2017-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:55 UTC |
READ IAN CDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 381,914 | $32.49 | $12,408,385.86 |
DisclosureSEC source: 0001225208-17-004783 · doc4.xml · nonDerivative · entry 3 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,738 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:55 UTC |
READ IAN CDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 201,441 | $34.06 | $6,861,080.46 |
DisclosureSEC source: 0001225208-17-004783 · doc4.xml · nonDerivative · entry 2 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 922,652 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:55 UTC |
READ IAN CDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 788,835 | $21.03 | $16,589,200.05 |
DisclosureSEC source: 0001225208-17-004783 · doc4.xml · nonDerivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,124,093 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:55 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 60,647 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004784 · doc4.xml · derivative · entry 7 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,647 Underlying: Common Stock · 60,647 shares Expires 2024-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:55 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 73,052 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004784 · doc4.xml · derivative · entry 6 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,052 Underlying: Common Stock · 73,052 shares Expires 2022-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:55 UTC |
SUSMAN SALLYExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 115,291 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-17-004784 · doc4.xml · derivative · entry 5 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 115,291 shares Expires 2017-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:55 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 55,818 | $32.49 | $1,813,526.82 |
DisclosureSEC source: 0001225208-17-004784 · doc4.xml · nonDerivative · entry 3 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,028 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:55 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 28,919 | $34.06 | $984,981.14 |
DisclosureSEC source: 0001225208-17-004784 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,846 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:55 UTC |
SUSMAN SALLYExecutive Vice President
|
Exercise / conversionCommon Stock | 115,291 | $21.03 | $2,424,569.73 |
DisclosureSEC source: 0001225208-17-004784 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:56 UTC |
YOUNG JOHN DGroup President
|
GrantStock Appreciation Rights · Derivative | 121,294 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004785 · doc4.xml · derivative · entry 8 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,294 Underlying: Common Stock · 121,294 shares Expires 2024-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:56 UTC |
YOUNG JOHN DGroup President
|
GrantStock Appreciation Rights · Derivative | 146,104 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004785 · doc4.xml · derivative · entry 7 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,104 Underlying: Common Stock · 146,104 shares Expires 2022-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:56 UTC |
YOUNG JOHN DGroup President
|
Exercise / conversionStock Appreciation Rights · Derivative | 51,578 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-17-004785 · doc4.xml · derivative · entry 6 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,578 shares Expires 2017-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:56 UTC |
YOUNG JOHN DGroup President
|
Tax withholdingCommon Stock | 24,971 | $32.49 | $811,307.79 |
DisclosureSEC source: 0001225208-17-004785 · doc4.xml · nonDerivative · entry 3 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,289 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:56 UTC |
YOUNG JOHN DGroup President
|
Tax withholdingCommon Stock | 10,282 | $34.06 | $350,204.92 |
DisclosureSEC source: 0001225208-17-004785 · doc4.xml · nonDerivative · entry 2 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,260 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:56 UTC |
YOUNG JOHN DGroup President
|
Exercise / conversionCommon Stock | 51,578 | $21.03 | $1,084,685.34 |
DisclosureSEC source: 0001225208-17-004785 · doc4.xml · nonDerivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 19:41 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 727 | $33.62 | $24,441.74 |
DisclosureSEC source: 0001225208-17-003714 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,791 Underlying: Common Stock · 727 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 23:54 UTC |
BOURLA ALBERTGroup President
|
GrantPhantom Stock Units SSP · Derivative | 38 | $33.47 | $1,271.86 |
DisclosureSEC source: 0001225208-17-000984 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,154 Underlying: Common Stock · 38 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 23:55 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 19 | $33.47 | $635.93 |
DisclosureSEC source: 0001225208-17-000985 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,940 Underlying: Common Stock · 19 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 23:55 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 38 | $33.47 | $1,271.86 |
DisclosureSEC source: 0001225208-17-000986 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,999 Underlying: Common Stock · 38 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 23:10 UTC |
LUND-JURGENSEN KIRSTENExecutive Vice President
|
Tax withholdingCommon Stock | 1,233 | $32.48 | $40,047.84 |
DisclosureSEC source: 0001225208-17-000508 · doc4.xml · nonDerivative · entry 1 LUND-JURGENSEN KIRSTEN · CIK 0001693493 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,523 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.